Cover Image

The role and therapeutic targeting of CCR5 in breast cancer

The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, rece...

Full description

Saved in:
Bibliographic Details
Main Authors: Hamid, Rasha (Author) , Alaziz, Mustafa (Author) , Mahal, Amanpreet S. (Author) , Ashton, Anthony W. (Author) , Halama, Niels (Author) , Jäger, Dirk (Author) , Jiao, Xuanmao (Author) , Pestell, Richard G. (Author)
Format: Article (Journal)
Language:English
Published: 2023
In: Cells
Year: 2023, Volume: 12, Issue: 18, Pages: 1-19
ISSN:2073-4409
DOI:10.3390/cells12182237
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cells12182237
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2073-4409/12/18/2237
Get full text
Author Notes:Rasha Hamid, Mustafa Alaziz, Amanpreet S. Mahal, Anthony W. Ashton, Niels Halama, Dirk Jaeger, Xuanmao Jiao and Richard G. Pestell
Description
Summary:The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.
Item Description:Veröffentlicht: 8. September 2023
Gesehen am 08.11.2023
Physical Description:Online Resource
ISSN:2073-4409
DOI:10.3390/cells12182237

Similar Items